Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: We performed a meta-analysis and systematic review to compare the radiotherapy (RT) modalities for hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT). Materials and methods: We searched the PubMed, EMBASE, Medline, and Cochrane library databases. The primary endpoint was the 1-year overall survival (OS), and response rate (RR), local control (LC), 2-year OS, and grade ≥3 toxicity incidence were evaluated as secondary endpoints. Results: Thirty-seven studies comprising 2513 patients were included. The pooled 1-year OS rates for the 3-dimensional conformal RT (3DCRT), selective internal RT (SIRT), and stereotactic body RT (SBRT) groups were 43.8% [95% confidence interval (CI): 37.6-50.2], 46.5% (95% CI: 37.7-55.6), and 48.5% (95% CI: 39.4-57.8). These inter-group differences were not statistically significant (p = 0.635). The pooled response rates were 51.3% (95% CI: 45.7-57.0), 33.3% (95% CI: 18.0-53.2), and 70.7 (95% CI: 63.7-76.8) for 3DCRT, SIRT, and SBRT groups, respectively; p = 0.001 and 0.031 for 3DCRT vs. SBRT and SIRT, respectively. The most common grade ≥ 3 complications were lymphocytopenia and bilirubin abnormalities in the 3DCRT and SIRT groups, respectively. Grade ≥ 3 complication was rare in SBRT group. Conclusions: OS did not differ among the modalities, although the response rates vary among modalities.

Original languageEnglish
JournalRadiotherapy and Oncology
DOIs
Publication statusAccepted/In press - 2017 Jan 1

Fingerprint

Portal Vein
Meta-Analysis
Hepatocellular Carcinoma
Thrombosis
Radiotherapy
Confidence Intervals
Survival Rate
Conformal Radiotherapy
Lymphopenia
Survival
Radiosurgery
Bilirubin
PubMed
Libraries
Databases
Incidence

Keywords

  • Hepatocellular carcinoma
  • Portal vein thrombosis
  • Radiotherapy
  • Selective internal radiotherapy
  • Stereotactic body radiotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

@article{5006f5c3a27b4b98847713a37c4b111b,
title = "Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review",
abstract = "Purpose: We performed a meta-analysis and systematic review to compare the radiotherapy (RT) modalities for hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT). Materials and methods: We searched the PubMed, EMBASE, Medline, and Cochrane library databases. The primary endpoint was the 1-year overall survival (OS), and response rate (RR), local control (LC), 2-year OS, and grade ≥3 toxicity incidence were evaluated as secondary endpoints. Results: Thirty-seven studies comprising 2513 patients were included. The pooled 1-year OS rates for the 3-dimensional conformal RT (3DCRT), selective internal RT (SIRT), and stereotactic body RT (SBRT) groups were 43.8{\%} [95{\%} confidence interval (CI): 37.6-50.2], 46.5{\%} (95{\%} CI: 37.7-55.6), and 48.5{\%} (95{\%} CI: 39.4-57.8). These inter-group differences were not statistically significant (p = 0.635). The pooled response rates were 51.3{\%} (95{\%} CI: 45.7-57.0), 33.3{\%} (95{\%} CI: 18.0-53.2), and 70.7 (95{\%} CI: 63.7-76.8) for 3DCRT, SIRT, and SBRT groups, respectively; p = 0.001 and 0.031 for 3DCRT vs. SBRT and SIRT, respectively. The most common grade ≥ 3 complications were lymphocytopenia and bilirubin abnormalities in the 3DCRT and SIRT groups, respectively. Grade ≥ 3 complication was rare in SBRT group. Conclusions: OS did not differ among the modalities, although the response rates vary among modalities.",
keywords = "Hepatocellular carcinoma, Portal vein thrombosis, Radiotherapy, Selective internal radiotherapy, Stereotactic body radiotherapy",
author = "Rim, {Chai Hong} and Kim, {Chul Yong} and Dae-Sik Yang and Yoon, {Won Sup}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.radonc.2017.11.013",
language = "English",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis

T2 - A meta-analysis and systematic review

AU - Rim, Chai Hong

AU - Kim, Chul Yong

AU - Yang, Dae-Sik

AU - Yoon, Won Sup

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose: We performed a meta-analysis and systematic review to compare the radiotherapy (RT) modalities for hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT). Materials and methods: We searched the PubMed, EMBASE, Medline, and Cochrane library databases. The primary endpoint was the 1-year overall survival (OS), and response rate (RR), local control (LC), 2-year OS, and grade ≥3 toxicity incidence were evaluated as secondary endpoints. Results: Thirty-seven studies comprising 2513 patients were included. The pooled 1-year OS rates for the 3-dimensional conformal RT (3DCRT), selective internal RT (SIRT), and stereotactic body RT (SBRT) groups were 43.8% [95% confidence interval (CI): 37.6-50.2], 46.5% (95% CI: 37.7-55.6), and 48.5% (95% CI: 39.4-57.8). These inter-group differences were not statistically significant (p = 0.635). The pooled response rates were 51.3% (95% CI: 45.7-57.0), 33.3% (95% CI: 18.0-53.2), and 70.7 (95% CI: 63.7-76.8) for 3DCRT, SIRT, and SBRT groups, respectively; p = 0.001 and 0.031 for 3DCRT vs. SBRT and SIRT, respectively. The most common grade ≥ 3 complications were lymphocytopenia and bilirubin abnormalities in the 3DCRT and SIRT groups, respectively. Grade ≥ 3 complication was rare in SBRT group. Conclusions: OS did not differ among the modalities, although the response rates vary among modalities.

AB - Purpose: We performed a meta-analysis and systematic review to compare the radiotherapy (RT) modalities for hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT). Materials and methods: We searched the PubMed, EMBASE, Medline, and Cochrane library databases. The primary endpoint was the 1-year overall survival (OS), and response rate (RR), local control (LC), 2-year OS, and grade ≥3 toxicity incidence were evaluated as secondary endpoints. Results: Thirty-seven studies comprising 2513 patients were included. The pooled 1-year OS rates for the 3-dimensional conformal RT (3DCRT), selective internal RT (SIRT), and stereotactic body RT (SBRT) groups were 43.8% [95% confidence interval (CI): 37.6-50.2], 46.5% (95% CI: 37.7-55.6), and 48.5% (95% CI: 39.4-57.8). These inter-group differences were not statistically significant (p = 0.635). The pooled response rates were 51.3% (95% CI: 45.7-57.0), 33.3% (95% CI: 18.0-53.2), and 70.7 (95% CI: 63.7-76.8) for 3DCRT, SIRT, and SBRT groups, respectively; p = 0.001 and 0.031 for 3DCRT vs. SBRT and SIRT, respectively. The most common grade ≥ 3 complications were lymphocytopenia and bilirubin abnormalities in the 3DCRT and SIRT groups, respectively. Grade ≥ 3 complication was rare in SBRT group. Conclusions: OS did not differ among the modalities, although the response rates vary among modalities.

KW - Hepatocellular carcinoma

KW - Portal vein thrombosis

KW - Radiotherapy

KW - Selective internal radiotherapy

KW - Stereotactic body radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85037655356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037655356&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2017.11.013

DO - 10.1016/j.radonc.2017.11.013

M3 - Article

C2 - 29233562

AN - SCOPUS:85037655356

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

ER -